Search Results

Antibe Therapeutics Inc. announced that the Toronto Stock Exchange is reviewing the eligibility for continued listing on the TSX of the securities of the Company.

Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE) announced that the Company sought an extension of its previously announced stay of proceedings (“ Stay ”) under the Companies’ Creditors Arrangement Act (the “ CCAA ”) at a hearing before the Ontario Superior Court of Justice (Commercial List) (the “ Court ”) on April 18, 2024.

Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies’ Creditors Arrangement Act (the " CCAA ").

Antibe Therapeutics Inc. is extending the Early Warrant Exercise Incentive Program for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.

Antibe Therapeutics Inc. announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commercialization of otenaproxesul in the Greater China region.

Antibe Therapeutics Inc. is pleased to announce a moderated poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended December 31, 2023.

Antibe Therapeutics Inc. is pleased to announce a poster presentation of data from otenaproxesul’s recent pharmacokinetic/pharmacodynamic (“PK/PD”) study.

Antibe Therapeutics Inc. announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration that otenaproxesul has been placed on clinical hold, postponing the initiation of the planned Phase II trial.